Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma-Reference-Cited by-同舟云学术

Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma

Published:2013-10-24 Issue:12 Volume:15 Page:1635-1643
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:Neuro-Oncology

Author:

Laxton R. C.,Popov S.,Doey L.,Jury A.,Bhangoo R.,Gullan R.,Chandler C.,Brazil L.,Sadler G.,Beaney R.,Sibtain N.,King A.,Bodi I.,Jones C.,Ashkan K.,Al-Sarraj S.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/15/12/1635/3985432/not125.pdf

Reference27 articles.

1. Long-term survival with glioblastoma multiforme

2. Molecular genetic alterations in glioblastomas with oligodendroglial component

3. Glioblastomas with an Oligodendroglial Component: A Pathological and Molecular Study

4. Histological indicators of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival

5. Correlation Among Pathology, Genotype, and Patient Outcomes in Glioblastoma

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort;Frontiers in Neurology;2023-01-09

2. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide;Cochrane Database of Systematic Reviews;2021-03-12

3. Histopathology of Adult and Pediatric Glioblastoma;Molecular Pathology Library;2021

4. The associations between preoperative conventional MRI features and genetic biomarkers status in newly diagnosed gbms: a clinical summary and prognostic analysis;Turkish Neurosurgery;2020

5. ATRX immunohistochemistry can help refine ‘not elsewhere classified’ categorisation for grade II/III gliomas;British Journal of Neurosurgery;2019-04-24